Hoth Therapeutics, Inc. (HOTH) Tuesday announced promising preclinical results for its investigational Alzheimer's drug, HT-ALZ. The company's shares were rising more than 15 percent in pre-market.
In the study, Alzheimer's model mice treated with HT-ALZ showed fewer reactive astrocytes compared to vehicle-treated group. Astrocytes, star-shaped cells found in the nervous system, become reactive in response to virtually all pathological conditions in the central nervous system. They play a role in the progression of neurodegenerative diseases like Alzheimer's. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive function, the company said in a statement.
"The reductions in astrocyte activity and the corresponding improvements in cognitive function observed with HT- ALZ give us confidence as we move forward in our development process," said Robb Knie, CEO of Hoth.
Hoth Therapeutics stock had closed at $1.01, down 8.18 percent on Monday. It has traded in the range of $0.5800 - $1.7900 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.